

CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.
You can purchase shares of CG Oncology (NASDAQ:CGON) through any online brokerage.
Other companies in CG Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
CG Oncology has a consensus price target of $71.94.
The stock price for CG Oncology (NASDAQ: CGON) is $61.99 last updated November 2, 2026 at 1:30 PM EST.
There are no upcoming dividends for CG Oncology.
CG Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for CG Oncology.
CG Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene...